Vandebroek Sophie V. 4

What Happened
Sophie Vandebroek, a director of IDEXX Laboratories (IDXX), exercised 945 stock options at a strike price of $333.90 (cost $315,536) on Feb 17, 2026, and sold shares in the open market the same day. She sold 945 shares at $628.65 (proceeds $594,070) and an additional 519 shares at $628.56 (proceeds $326,223), for total gross sale proceeds of $920,293. The sequence (exercise followed by same-day sales) indicates a cashless-type exercise where newly acquired shares were largely sold immediately.

Key Details

• Transaction date: 2026-02-17; Form 4 filed: 2026-02-19 (timely within the two-business-day window).
• Option exercise: 945 shares exercised at $333.90 each — total cost $315,536 (transaction code M).
• Open-market sales: 945 shares at $628.65 ($594,070) and 519 shares at $628.56 ($326,223) (transaction code S).
• Total shares sold: 1,464; total sale proceeds: $920,293; approximate net proceeds after exercise cost: ~$604,757.
• Footnote F1: The exercised option grant vested in one installment on the one-year anniversary of the grant or at the 2023 annual meeting, whichever was earlier. Footnote F2: Not applicable.
• Shares owned after the transactions are not specified in the provided excerpt of the filing.

Context
An exercise followed by immediate sales is common for option holders needing to cover the exercise cost and taxes; it does not necessarily signal a view on the company’s prospects. Vandebroek is a director (not reported here as a 10% owner or executive officer), and the filing shows routine insider liquidity rather than a new open-market purchase.